JNJ - Johnson & Johnson

NYSE - NYSE Delayed Price. Currency in USD
141.98
+1.52 (+1.08%)
At close: 4:00PM EDT

141.90 -0.08 (-0.06%)
After hours: 4:50PM EDT

Stock chart is not supported by your current browser
Previous Close140.46
Open140.82
Bid141.98 x 800
Ask141.90 x 800
Day's Range140.51 - 142.14
52 Week Range118.62 - 148.32
Volume4,927,533
Avg. Volume6,106,282
Market Cap380.898B
Beta0.53
PE Ratio (TTM)282.27
EPS (TTM)0.50
Earnings DateOct 16, 2018
Forward Dividend & Yield3.60 (2.58%)
Ex-Dividend Date2018-08-27
1y Target Est143.79
Trade prices are not sourced from all markets
  • Here’s a clear case for owning dividend stocks instead of bonds
    MarketWatch3 hours ago

    Here’s a clear case for owning dividend stocks instead of bonds

    Hank Smith, co-chief investment officer of Haverford Trust, has laid out a clear case for dividend stocks over bonds. Pepsi’s stock had a dividend yield of 3.25% as of the close on Sept. 18, while 10-year U.S. Treasury paper yielded 3.05%.

  • Analysts Are Overwhelmingly Bullish on Abbott Laboratories
    Market Realist5 hours ago

    Analysts Are Overwhelmingly Bullish on Abbott Laboratories

    Abbott Laboratories (ABT) is one of the leading medical technology companies in the world. It offers products across its Medical Devices, Nutrition, Diagnostics, and Established Pharmaceuticals segments, with most of its products having the highest market shares in their respective markets. On July 18, the company released its most recent quarterly results and exceeded analysts’ estimates.

  • Lake Nona appears set to land big biotech facility
    American City Business Journals7 hours ago

    Lake Nona appears set to land big biotech facility

    Before dirt even has been tossed, a future biotech manufacturing plant in Lake Nona’s 650-acre Medical City is dreaming up expansion plans. The 18-acre site — likely slated for Cranbury, N.J.-based global tech and biopharmaceutical company Amicus Therapeutics Inc. (Nasdaq: FOLD) — already is being considered for a planned development with manufacturing, office and warehouse space. Real estate sources said Amicus likely is the company behind Project Olympus.

  • What Quest Diagnostics’ Valuation Trend Indicates
    Market Realist9 hours ago

    What Quest Diagnostics’ Valuation Trend Indicates

    In September 2018, of the total 18 analysts covering Quest Diagnostics (DGX), ten analysts have given Quest stock a “buy” or higher rating, and eight analysts have given Quest a “hold” rating. The mean rating for Quest stock is 2.22 with a target price of $116.86 implying an upside potential of 9% over Quest’s closing price of $107.22 on September 18, 2018.

  • Pharma Stocks: Merck & Co.’s Revenue Trend and 2018 Estimates
    Market Realist9 hours ago

    Pharma Stocks: Merck & Co.’s Revenue Trend and 2018 Estimates

    Merck & Co. reported a rise of 5% in its top line to ~$10.5 billion in the second quarter, including a 4% rise in operating revenue and a 1% favorable impact of foreign exchange. This revenue growth was driven by the strong sales of Keytruda, the Gardasil franchise, ProQuad/Varivax, RotaTeq, Pneumovax 23, Bridion, Noxafil, Simponi, Belsomra, Isentress, Januvia, Janumet, Atozet, Adempas, and a few other drugs from its pharmaceutical business.

  • Johnson & Johnson to Host Investor Conference Call on Third-Quarter Results
    PR Newswireyesterday

    Johnson & Johnson to Host Investor Conference Call on Third-Quarter Results

    The webcast and presentation material are accessible at Johnson & Johnson's website www.investor.jnj.com. A replay of the webcast will be available approximately three hours after the conference call concludes.

  • Taking Stock of Quest Diagnostics’ Recent Acquisitions
    Market Realistyesterday

    Taking Stock of Quest Diagnostics’ Recent Acquisitions

    Quest Diagnostics’ (DGX) diagnostic information services (or DIS) business accounts for more than 95% of the company’s total revenues. It is characterized by a high volume of relatively low-dollar transactions. Under DIS, Quest provides clinical testing and other services. Major customer groups for DIS include healthcare insurers, government payers, client payers, and patients.

  • How Quest Diagnostics Is Positioned in 2018
    Market Realistyesterday

    How Quest Diagnostics Is Positioned in 2018

    Quest Diagnostics (DGX) is a leading provider of diagnostic information services. Quest makes use of its database of clinical lab results to gain diagnostic insights that help to improve healthcare management. Quest’s diagnostics information services business (or DIS) provides data and insights based on routine, non-routine, and advanced clinical testing, as well as anatomic pathology testing and other diagnostic information services.

  • J&J Files NDA for Erdafitinib in Urothelial Cancer Indication
    Zacksyesterday

    J&J Files NDA for Erdafitinib in Urothelial Cancer Indication

    Johnson & Johnson (JNJ) submits regulatory application to the FDA seeking approval of pan-FGFR inhibitor, erdafitinib, for the treatment of metastatic urothelial cancer, a type of bladder cancer.

  • Benzingayesterday

    The Daily Biotech Pulse: Johnson & Johnson's Generic Unit Files NDA For Urinary Tract Cancer Drug, G1 Therapeutics Prices Offering

    Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Sept. 18.) Boston Scientific Corporation (NYSE: BSX ) Cara Therapeutics ...

  • MarketWatch2 days ago

    Health care ETF surges toward record in a broad sector rally

    The SPDR Health Care Select Sector ETF rose 0.7% toward a record high in afternoon trade Tuesday, with 55 of its 63 equity components gaining ground. Among the ETF's (XLV) members which are also Dow Jones Industrial Average components, Pfizer Inc.'s stock shot up 1.5%, putting it on track to close at the highest level since December 2001. Also, shares of Johnson & Johnson gained 0.6% toward an eight-month high, Merck & Co. Inc. tacked on 0.4% to sit just shy of its 17-year high reached last Thursday, and UnitedHealth Group Inc. slipped 0.1% and was 2.2% below its Sept. 6 record close of $269.65. The XLV's biggest gainer was Abiomed Inc.'s stock , which rallied 2.7%, while its biggest decliner was AbbVie Inc.'s stock , which shed 2.1% after California sued the company alleging the payment of illegal kickbacks. The XLV has rallied 11% over the past three months, while the Dow has tacked on 5.2%.

  • Reuters3 days ago

    Exclusive - India, U.S. closing in on package deal to remove trade irritants

    Indian farmers and U.S. manufacturers of medical devices could be among the main winners in a trade package under negotiation, as Washington and New Delhi look to remove long-standing irritants to ties, sources familiar with the talks said. Having skirmished for months over tit-for-tat tariffs on steel and some agricultural products, the two sides began talks in June that also cover India's concerns over U.S. steel tariffs and U.S. problems with Indian tariffs on imported IT equipment. U.S. President Donald Trump, who dislikes multilateral trade agreements, said earlier this month that India had approached the United States to "start doing a trade deal," without giving any details.

  • InvestorPlace3 days ago

    Cronos Gets Bigger As It Partners With Ginkgo Bioworks

    From the looks of Cronos Group, Inc. (NASDAQ:CRON) on the charts, the stock looked like it topped around $13 and is on the way down. On Sept. 4, Cronos announced a partnership with Ginkgo Bioworks. It will produce cultured cannabinoid, the active ingredient produced in cannabis plants.

  • Glaxo Seeks EU Approval for Two-Drug Regimen in First-Line HIV
    Zacks3 days ago

    Glaxo Seeks EU Approval for Two-Drug Regimen in First-Line HIV

    Glaxo (GSK) submits a regulatory application in the EU for a single-tablet, two-drug regimen of dolutegravir and lamivudine for the first-line treatment of HIV-1 infection.

  • Pfizer's Skin Disease Candidates Positive in Mid-Stage Study
    Zacks3 days ago

    Pfizer's Skin Disease Candidates Positive in Mid-Stage Study

    Pfizer's (PFE) JAK inhibitor candidates -- PF-06651600 and PF-06700841 -- demonstrate improvements in moderate to severe alopecia areata patients in a phase II study.

  • J&J Talc Supplier Takes No Chances on Another Big Jury Loss
    Bloomberg3 days ago

    J&J Talc Supplier Takes No Chances on Another Big Jury Loss

    Imerys SA, which supplies talc to Johnson & Johnson, isn’t taking chances as another jury weighs whether to sock the health-care giant with a punishing verdict. A unit of Imerys agreed to settle its part of a California woman’s lawsuit blaming both companies for causing her cancer with asbestos-tainted talc at the conclusion of a four-week state-court trial in Pasadena, just before the case was sent to jury for deliberations. In July, a St. Louis jury ordered J&J to pay $4.69 billion in damages to 22 women who blamed their ovarian cancer on exposure to asbestos in the company’s powders.

  • Why Johnson & Johnson (JNJ) Could Beat Earnings Estimates Again
    Zacks3 days ago

    Why Johnson & Johnson (JNJ) Could Beat Earnings Estimates Again

    Johnson & Johnson (JNJ) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

  • Is Artificial Intelligence the Next Big Thing in Biotech?
    Zacks3 days ago

    Is Artificial Intelligence the Next Big Thing in Biotech?

    Artificial intelligence can drastically reduce the time taken to develop new life-saving drugs.

  • Wall Street Analysts Are Mostly Positive on Merck in September
    Market Realist6 days ago

    Wall Street Analysts Are Mostly Positive on Merck in September

    Merck (MRK) recently announced that its pivotal Phase 3 trial that evaluated Zerbaxa met its primary endpoint. Zerbaxa is an investigational antibiotic for the treatment of adult individuals with ventilated hospital-acquired bacteria pneumonia or ventilator-associated bacterial pneumonia (or VABP). Zerbaxa demonstrated non-inferiority compared to meropenem.

  • Benzinga6 days ago

    Pacira Shares Look Expensive, Stifel Says In Bearish Initiation

    Despite the recent upward momentum in Pacira Pharmaceuticals Inc (NASDAQ: PCRX ) shares, Stifel is taking a bearish stance on the stock.  The Analyst Analyst Derek Archila initiated coverage of Pacira ...

  • Pharma/Biotech Stocks to Watch This Prostate Cancer Month
    Zacks6 days ago

    Pharma/Biotech Stocks to Watch This Prostate Cancer Month

    Here we highlight a few companies that are focused on developing treatments for prostate cancer.

  • Johnson & Johnson’s Recent Development in HIV
    Market Realist6 days ago

    Johnson & Johnson’s Recent Development in HIV

    On August 15, Johnson & Johnson (JNJ) and ViiV Healthcare, the HIV business subsidiary of GlaxoSmithKline (GSK), announced positive top-line results of their Phase 3 ATLAS (Antiretroviral Therapy as Long-Acting Suppression) trial. The regimen consists of Johnson & Johnson’s rilpivirine and ViiV Healthcare’s cabotegravir, which is injected once per month. The study evaluated this 2DR therapy with the standard of care three-drug daily oral regimen.

  • Johnson & Johnson Expands Blood Cancer Portfolio with Approval
    Market Realist6 days ago

    Johnson & Johnson Expands Blood Cancer Portfolio with Approval

    On August 27, Johnson & Johnson (JNJ) announced that it received FDA approval for its combination therapy of Imbruvica and Roche’s (RHHBY) rituximab for the treatment of WM (Waldenström’s macroglobulinemia), a rare blood cancer. According to JNJ, ~2,800 new WM cases are reported each year in the United States.

  • 5 Dow Jones Stocks That Are Gaining New Ground
    InvestorPlace7 days ago

    5 Dow Jones Stocks That Are Gaining New Ground

    Other catalysts encouraging investors include a relatively tame August inflation report and little in the way of surprises from policy updates by the European Central Bank and the Bank of England. As a result, a number of Dow Jones Industrial Average companies are perking up in a big way. Apple (NASDAQ:AAPL) shares are continuing to rally off of their 20-day moving average in a possible retest of the early September record high.

  • Allergan Unveils Spotlyte, Its First Digital Ventures Launch
    Market Realist7 days ago

    Allergan Unveils Spotlyte, Its First Digital Ventures Launch

    On September 12, Allergan (AGN) announced the launch of Spotlyte, the first launch from Project Moonwalker, the Allergan-owned digital ventures unit. Spotlyte is an innovative digital hub designed to educate consumers about medical aesthetic treatments. The below chart lists key updates on Spotlyte. Spotlyte is the first venture from Project Moonwalker and is designed to educate consumers about medical aesthetics.